id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_d4jlapbsgrgz7cb75izz4pq2iu	Noah M. Hahn	A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157	2016	10	.pdf	application/pdf	8708	1054	55	Calmette-Guerin (BCG)-unresponsive NMIUC (>2 prior intravesical regimens) with increased phosphorylated FGFR3 (pFGFR3) in metastatic patients with urothelial carcinoma combining chemotherapy with the anti-VEGFR2 monoclonal antibody bevacizumab have demonstrated promising overall survival outcomes mutations are highly associated with low-grade NMIUC, overexpression of FGFR3 has been observed in up to 42% of highgrade muscle-invasive urothelial carcinoma tumors (22). frequent FGFR3 aberrations in NMIUC, we conducted a multisite pilot trial in patients with BCG-unresponsive NMIUC harboring FGFR3 gene alterations to evaluate the clinical and biologic This trial reports the toxicity, pharmacodynamics, and clinical efficacy profiles of the oral FGFR1-3 and VEGFR1-3 multitargeted tyrosine kinase inhibitor, dovitinib, in a pilot phase II (BCG)-unresponsive non–muscle-invasive urothelial carcinoma of the bladder (NMIUC) with tumors harboring FGFR3 patients with tumors demonstrating no FGFR3 mutations were Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or	./cache/work_d4jlapbsgrgz7cb75izz4pq2iu.pdf	./txt/work_d4jlapbsgrgz7cb75izz4pq2iu.txt